About
Mission & Values
Leadership
Board of Directors
Collaborators
History
Contact Us
Platform
Human-First Discovery
®
Platform
IP Portfolio
Publications
Pipeline
Overview
Programs
Investors & News
Overview
Stock Information
Press Releases
Events & Presentations
Publications
Financials & Filings
Corporate Governance
Investor Resources
Contact IR
Careers
Overview
Open Positions
Press release
CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent
C. difficile
Infection: A Combined Analysis of the PRISM3 (Randomized Placebo-Controlled) and PRISM-EXT (Open-Label) Trials
Media contact:
Gabriella Linville-Engler
[email protected]
Investor contact:
Greg Perry
[email protected]
Contact us
[email protected]
617-229-6499
200 Inner Belt Road,
Suite 400, Somerville, MA, 02143
Policies
© 2023 Finch Therapeutics Group, Inc. All rights reserved.